Searched for
SHILPA MEDICARE SHARES
Q4 earnings roundup: Raymond Realty, MCX among 19 companies that delivered 100%+ growth in sales and PATA select group of 19 large-cap BSE-listed companies achieved triple-digit growth in both profit and revenue during Q4FY26, indicating stron...- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Stock to watch: Shilpa Medicare stock in focus after receiving CEP from EDQM for diabetes drugShares of Shilpa Medicare will be highlighted as its subsidiary, Shilpa Pharma Lifesciences, obtained a certificate of suitability from Eur...
- Shilpa Medicare completes phase-3 trial of novel therapy against nonalcoholic fatty liver disease, shares gainShilpa Medicare's shares surged 6.40% on BSE following the successful phase-3 clinical trials of Nor Ursodeoxycholic Acid tablets for Nonal...
- Reduce Shilpa Medicare, target price Rs 346: ICICI SecuritiesShilpa Medicare Ltd., incorporated in the year 1987, is a Small Cap company (having a market cap of Rs 3384.41 Crore) operating in Pharmace...
- India's Shilpa Medicare to make Cadila's COVID-19 vaccineThe country's health authorities had given emergency approval in August for Cadila's vaccine, the world's first COVID-19 DNA shot, in adult...
- NSE-BSE bulk deals: HDFC Mutual Fund raises stake in Power MechPinewood Strategy’s India Opportunities Growth Fund bought 8,70,000 Shilpa Medicare shares through a bulk deal at Rs 511 per share.
- Shilpa Medicare zooms 26% in 2 days after DRL vaccine dealIn five consecutive sessions, the counter has surged 30 per cent.
- Shilpa Medicare jumps 12% after inking vaccine deal with DRLThe company has entered into a three-year agreement with Dr Reddy's Laboratories Limited (DRL) for the production of Sputnik V vaccine for ...
- Shilpa Medicare gets tentative American health regulator nod for Apremilast tabletsThe company has received tentative approval from US Food and Drug Administration for its abbreviated new drug application (ANDA) Apremilast...
- Trending stocks: Shilpa Medicare shares jump 5%The stock quoted a 52-week high of Rs 537.0 and a 52-week low of Rs 208.1.
- Shilpa Medicare shares hit lower circuit after USFDA observations for Telangana unitThe US Food and Drug Administration (USFDA) issued form 483 with 15 observations to the company’s Jadcherla Unit
- Shilpa Medicare gets USFDA nod for cancer drugShilpa Medicare has received USFDA final approval for its abbreviated new drug application.
- Shilpa Medicare gets USFDA nod for cancer treatment injectionShares of Shilpa Medicare were trading 3.80 per cent up at Rs 398.65 apiece on BSE.
- Shilpa Medicare gets tentative USFDA nod for multiple sclerosis drugThe company's abbreviated new drug application (ANDA) for Dimethyl Fumarate delayed release capsules in the strengths of 120 mg and 240 mg ...
- TA Associates picks up 4% stake in publicly traded Shilpa MedicareTA Associates subscribed to 30,25,000 shares at Rs. 570/share as per a stock exchange filing by Shilpa Medicare earlier today.
- Shilpa Medicare inks pact with MPP, Gilead for HIV/AIDS drugsShilpa Medicare inked an agreement with Gilead Sciences to increase access to medicines used for treatment of HIV/AIDS.
- Shilpa Medicare acquires controlling stake in Nu TherapeuticsDrug firm Shilpa Medicare today said it has acquired a controlling stake in Hyderabad-based Nu Therapeutics for an undisclosed sum.
- Shilpa Medicare gets suitability certificate for Oxaliplatin EPShilpa Medicare has received the certificate of suitability of Monographs from European Directorate for the Quality of Medicines for the ac...
- Shilpa Medicare to acquire Austria's LOBA FinchemieShilpa Medicare has entered into an understanding to acquire Austria’s LOBA Finchemie in an all-cash deal.
Load More
